Citations

Clear

511 citation(s) found for "Seth, N".

Associations of Nocturnal Blood Pressure With Cognition by Self‐Identified Race in Middle‐Aged and Older Adults: The GENOA (Genetic Epidemiology Network of Arteriopathy) Study
Yano, Yuichiro , Butler, Kenneth R. , Hall, Michael E. , Schwartz, Gary L. , Lirette, Seth T. , Wilson, James G. , Hall, John E. , Turner, Stephen T. , Butler, Kenneth R , Knopman, David S. , Jones, Daniel W. , Correa, Adolfo , Mosley, Thomas H. , Lirette, Seth

Mayo Clinic

Journal of the American Heart Association | October 28, 2017 | Volume: 6 | Issue: 11 | Pages: No page available

10.1161/jaha.117.007022 | PMID 29079569 Get It

Background Whether the association of blood pressure ( BP ) during sleep (nocturnal BP ) with cognition differs by race is unknown. Methods and Results Participants in the GENOA (Genetic Epidemiology Network of Arteriopathy) Study underwent ambulatory BP measurements, brain magnetic resonance imaging, and cognitive function testing (the Rey Auditory Verbal Learning Test, the Digit Symbol Substitution Task, and the Trail Making Test Part B) between 2000 and 2007. We examined multivariable linear regression models of the nocturnal BP ‐cognition association. Among 755 participants (mean age, 63 years; 64% women; 42% self‐identified black race; 76% taking antihypertensive medication), mean nocturnal systolic BP ( SBP )/diastolic BP was 126/69 mm Hg, daytime SBP / diastolic BP level was 139/82 mm Hg, and mean reduction in SBP from day to night (dipping) was 9%. Among the entire sample, a race interaction was observed in Digit Symbol Substitution Task and Trail Making Test Part B (both P <0.15). Race‐stratified analyses showed that a 1‐ SD increase in nocturnal SBP levels was associated with poorer Digit Symbol Substitution Task and log‐transformed Trail Making Test Part B scores (unstandardized regression coefficient [95% confidence interval ]: −1.98 [−3.28 to −0.69] and 0.06 [0.004–0.12]; both P< 0.05) in black but not white individuals. Additional adjustments for white matter hyperintensity volumes or brain atrophy, measured via brain magnetic resonance imaging, did not change the results. Results were similar when nocturnal SBP dipping was assessed as the exposure, yet daytime SBP levels yielded no association with cognition. Conclusions Nocturnal SBP measurements may be useful in assessing the potential risk for lower cognitive function in middle‐aged and older adults, particularly in black individuals.
Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis
Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Endo, Itaru , Iwashita, Yukio , Hibi, Taizo , Pitt, Henry A. , Umezawa, Akiko , Asai, Koji , Hwang, Tsann‐Long , Mori, Yasuhisa , Huang, Wayne Shih‐Wei, Belli, Giulio, Dervenis, Christos, Yokoe, Masamichi, Kiriyama, Seiki , Itoi, Takao , Jagannath, P., Garden, O. James , Miura, Fumihiko, Wakabayashi, Go , Cherqui, Daniel , Santibáñes, Eduardo de , Shikata, Satoru , Noguchi, Yoshinori , Higuchi, Ryota , Wada, Keita, Supe, Avinash , Yoshida, Masahiro , Mayumi, Toshihiko , Gouma, Dirk J., Deziel, Daniel J., Liau, Kui‐Hin, Chen, Miin‐Fu , Shibao, Kazunori , Liu, Keng‐Hao, Su, Cheng‐Hsi, Chan, Angus C. W., Choi, In‐Seok , Jonas, Eduard , Fan, Sheung Tat , Ker, Chen‐Guo , Giménez, Mariano , Kitano, Seigo, Inomata, Masafumi , Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Nakamura, Masafumi , Horiguchi, Akihiko , Ukai, Tomohiko , Honda, Goro , Yoon, Dong Sup , Chen, Xiaoping , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | October 16, 2017 | Volume: 25 | Issue: 1 | Pages: 55-72

10.1002/jhbp.516 | PMID 29045062 Get It

Abstract We propose a new flowchart for the treatment of acute cholecystitis ( AC ) in the Tokyo Guidelines 2018 (TG18). Grade III AC was not indicated for straightforward laparoscopic cholecystectomy (Lap‐C). Following analysis of subsequent clinical investigations and drawing on Big Data in particular, TG 18 proposes that some Grade III AC can be treated by Lap‐C when performed at advanced centers with specialized surgeons experienced in this procedure and for patients that satisfy certain strict criteria. For Grade I, TG 18 recommends early Lap‐C if the patients meet the criteria of Charlson comorbidity index ( CCI ) ≤5 and American Society of Anesthesiologists physical status classification ( ASA ‐ PS ) ≤2. For Grade II AC , if patients meet the criteria of CCI ≤5 and ASA ‐ PS ≤2, TG 18 recommends early Lap‐C performed by experienced surgeons; and if not, after medical treatment and/or gallbladder drainage, Lap‐C would be indicated. TG 18 proposes that Lap‐C is indicated in Grade III patients with strict criteria. These are that the patients have favorable organ system failure, and negative predictive factors, who meet the criteria of CCI ≤3 and ASA ‐ PS ≤2 and who are being treated at an advanced center (where experienced surgeons practice). If the patient is not considered suitable for early surgery, TG 18 recommends early/urgent biliary drainage followed by delayed Lap‐C once the patient's overall condition has improved. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos)
Yokoe, Masamichi, Hata, Jiro , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Wakabayashi, Go , Kozaka, Kazuto , Endo, Itaru , Deziel, Daniel J., Miura, Fumihiko, Okamoto, Kohji , Hwang, Tsann‐Long , Huang, Wayne Shih‐Wei, Ker, Chen‐Guo , Chen, Miin‐Fu , Choi, In‐Seok , Noguchi, Yoshinori , Shikata, Satoru , Higuchi, Ryota , Gabata, Toshifumi , Mori, Yasuhisa , Iwashita, Yukio , Hibi, Taizo , Jagannath, P., Jonas, Eduard , Liau, Kui‐Hin, Dervenis, Christos, Gouma, Dirk J., Cherqui, Daniel , Belli, Giulio, Garden, O. James , Giménez, Mariano , Santibáñes, Eduardo de , Umezawa, Akiko , Supe, Avinash , Pitt, Henry A. , Singh, Harjit , Chan, Angus C. W., Lau, Wan Yee , Sugioka, Atsushi , Asai, Koji , Gomi, Harumi , Itoi, Takao , Kiriyama, Seiki , Yoshida, Masahiro , Mayumi, Toshihiko , Matsumura, Naoki , Tokumura, Hiromi, Kitano, Seigo, Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Han, Ho-Seong , Yoon, Yoo-Seok , Yoon, Dong Sup , Ukai, Tomohiko , Suzuki, Kenji S. , Teoh, Anthony Yuen Bun , Honda, Goro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | October 15, 2017 | Volume: 25 | Issue: 1 | Pages: 41-54

10.1002/jhbp.515 | PMID 29032636 Get It

Abstract The Tokyo Guidelines 2013 (TG13) for acute cholangitis and cholecystitis were globally disseminated and various clinical studies about the management of acute cholecystitis were reported by many researchers and clinicians from all over the world. The 1 st edition of the Tokyo Guidelines 2007 ( TG 07) was revised in 2013. According to that revision, the TG 13 diagnostic criteria of acute cholecystitis provided better specificity and higher diagnostic accuracy. Thorough our literature search about diagnostic criteria for acute cholecystitis, new and strong evidence that had been released from 2013 to 2017 was not found with serious and important issues about using TG 13 diagnostic criteria of acute cholecystitis. On the other hand, the TG 13 severity grading for acute cholecystitis has been validated in numerous studies. As a result of these reviews, the TG 13 severity grading for acute cholecystitis was significantly associated with parameters including 30‐day overall mortality, length of hospital stay, conversion rates to open surgery, and medical costs. In terms of severity assessment, breakthrough and intensive literature for revising severity grading was not reported. Consequently, TG 13 diagnostic criteria and severity grading were judged from numerous validation studies as useful indicators in clinical practice and adopted as TG 18/ TG 13 diagnostic criteria and severity grading of acute cholecystitis without any modification. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014
McDermott, L. A., Jenkins, Stephen G., Goldstein, Ellie J. C., Forbes, Betty A., Gerding, Dale N. , Thorpe, Cheleste M. , Walk, Seth T. , Snydman, David R. , Patel, Robin , Johnson, Stuart

Mayo Clinic

Open Forum Infectious Diseases | October 4, 2017 | Volume: 4 | Issue: suppl_1 | Pages: S391-S391

10.1093/ofid/ofx163.973 Get It

Abstract Background Trends in the distribution of ribotypes for C. difficile associated diarrheal isolates obtained over time in the United States are lacking. As part of surveillance program for C. difficile susceptibility, we analyzed stool isolates for ribotype distribution from a phase 2 trial of surotomycin (2010–2011) (North America sites) as well as a national surveillance study from 2011–2014. Isolates for the surveillance study were referred from 6 geographically distinct medical centers. Methods C. difficile isolates or C. difficile toxin + stools from patients with C. difficile associated diarrhea (CDAD) were submitted for testing to Tufts Medical Center. Following isolation and confirmation as C. difficile, a random sample of isolates were ribotyped by PCR capillary gel electrophoresis. Results 673 isolates over the 5 years of the analysis have been ribotyped to date. There were 49 unique ribotype designations, and 16 ribotypes had more than 10 isolates. The ribotype distribution by year is shown in the table. Conclusion There has been a change in the frequency of ribotypes over time in the US. Of the most common ribotypes seen, 027 has decreased by over 50% while there has been an increase of 014-020, 002, and 106. 014-020 is now the most common ribotype seen in the US. These data suggest that there is a changing epidemiology of C. difficile in the US and continuous monitoring of the ribotype distributions and clinical implications is warranted. Disclosures D. R. Snydman, Merck: Consultant and Grant Investigator, Consulting fee and Research grant; Shire: Consultant, Consulting fee; Summit PLC: Consultant and Grant Investigator, Consulting fee and Research grant; BioK+: Consultant, Consulting fee; Actelion: Grant Investigator, Research grant; S. G. Jenkins, Cormedix: Consultant, Consulting fee; Bayer: Consultant, Consulting fee; Merck: Grant Investigator and Scientific Advisor, Research grant; E. J. C. Goldstein, Merck: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee and Grant recipient; Cubist: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee; Actelion: Grant Investigator, Grant recipient; Summit PLC: Grant Investigator and Scientific Advisor, Grant recipient; R. Patel, Curetis: Consultant, Grant Investigator and Speaker’s Bureau, Consulting fee and Research grant; Pocared: Grant Investigator, Research grant; nanoMR: Grant Investigator, Research grant; BioFire: Grant Investigator, Research grant; Check-Points: Grant Investigator, Research grant; 3M: Grant Investigator, Research grant; Cubist: Grant Investigator, Research grant; Merck: Grant Investigator, Research grant; S. Johnson, Bio-K+: Consultant, Consulting fee; D. N. Gerding, Merck, Shire, Cubist, Rebiotix, sanofi pasteur, Summit, DaVoltera, Actelion: Consultant, Consulting fee; CDC, US Dept of Veterans Affairs Research Service: Grant Investigator, Research grant
Young woman with segmental colitis
Anderson, Bradley W., Sweetser, Seth , Imam, Zaid

Mayo Clinic

Gut | September 12, 2017 | Volume: 67 | Issue: 8 | Pages: 1399-1474

10.1136/gutjnl-2017-315122 | PMID 28899985 Get It

Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos)
Mori, Yasuhisa , Itoi, Takao , Baron, Todd H. , Takada, Tadahiro , Strasberg, Steven M. , Pitt, Henry A. , Ukai, Tomohiko , Shikata, Satoru , Noguchi, Yoshinori , Kim, Myung‐Hwan , Asbun, Horacio J. , Endo, Itaru , Yokoe, Masamichi, Miura, Fumihiko, Okamoto, Kohji , Umezawa, Akiko , Iwashita, Yukio , Hibi, Taizo , Wakabayashi, Go , Choi, In‐Seok , Hwang, Tsann‐Long , Chen, Miin‐Fu , Garden, O. James , Singh, Harjit , Liau, Kui‐Hin, Huang, Wayne Shih‐Wei, Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Santibáñes, Eduardo de , Giménez, Mariano , Windsor, John A. , Lau, Wan Yee , Cherqui, Daniel , Jagannath, P., Supe, Avinash , Liu, Keng‐Hao, Su, Cheng‐Hsi, Deziel, Daniel J., Fan, Sheung Tat , Ker, Chen‐Guo , Jonas, Eduard , Padbury, Robert , Sugioka, Atsushi , Asai, Koji , Higuchi, Ryota , Wada, Keita, Yoshida, Masahiro , Mayumi, Toshihiko , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Teoh, Anthony Yuen Bun , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Chen, Xiao‐Ping , Mukai, Shuntaro , Honda, Goro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | September 9, 2017 | Volume: 25 | Issue: 1 | Pages: 87-95

10.1002/jhbp.504 | PMID 28888080 Get It

Abstract Since the publication of the Tokyo Guidelines in 2007 and their revision in 2013, appropriate management for acute cholecystitis has been more clearly established. Since the last revision, several manuscripts, especially for alternative endoscopic techniques, have been reported; therefore, additional evaluation and refinement of the 2013 Guidelines is required. We describe a standard drainage method for surgically high‐risk patients with acute cholecystitis and the latest developed endoscopic gallbladder drainage techniques described in the updated Tokyo Guidelines 2018 ( TG 18). Our study confirmed that percutaneous transhepatic gallbladder drainage should be considered the first alternative to surgical intervention in surgically high‐risk patients with acute cholecystitis. Also, endoscopic transpapillary gallbladder drainage or endoscopic ultrasound‐guided gallbladder drainage can be considered in high‐volume institutes by skilled endoscopists. In the endoscopic transpapillary approach, either endoscopic naso‐gallbladder drainage or gallbladder stenting can be considered for gallbladder drainage. We also introduce special techniques and the latest outcomes of endoscopic ultrasound‐guided gallbladder drainage studies. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Delphi consensus on bile duct injuries during laparoscopic cholecystectomy: an evolutionary cul‐de‐sac or the birth pangs of a new technical framework?
Iwashita, Yukio , Hibi, Taizo , Ohyama, Tetsuji , Umezawa, Akiko , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Pitt, Henry A. , Hwang, Tsann‐Long , Choi, In‐Seok , Yoon, Dong Sup , Huang, Wayne Shih‐Wei, Yoshida, Masahiro , Wakabayashi, Go , Miura, Fumihiko, Okamoto, Kohji , Endo, Itaru , Santibáñes, Eduardo de , Giménez, Mariano , Windsor, John A. , Garden, O. James , Gouma, Dirk J., Cherqui, Daniel , Belli, Giulio, Dervenis, Christos, Deziel, Daniel J., Jonas, Eduard , Jagannath, P., Supe, Avinash , Singh, Harjit , Liau, Kui‐Hin, Chan, Angus C. W., Lau, Wan Yee , Fan, Sheung Tat , Chen, Miin‐Fu , Kim, Myung‐Hwan , Sugioka, Atsushi , Asai, Koji , Wada, Keita, Mori, Yasuhisa , Higuchi, Ryota , Misawa, Takeyuki , Matsumura, Naoki , Rikiyama, Toshiki, Kano, Nobuyasu, Tokumura, Hiromi, Kimura, Taizo, Kitano, Seigo, Inomata, Masafumi , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Han, Ho-Seong , Suzuki, Kenji S. , Yoon, Yoo-Seok , Chen, Xiao‐Ping , Honda, Goro , Watanabe, Manabu , Sata, Naohiro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | September 8, 2017 | Volume: 24 | Issue: 11 | Pages: 591-602

10.1002/jhbp.503 | PMID 28884962 Get It

Abstract Bile duct injury ( BDI ) during laparoscopic cholecystectomy remains a serious iatrogenic surgical complication. BDI most often occurs as a result of misidentification of the anatomy; however, clinical evidence on its precise mechanism and surgeons’ perceptions is scarce. Surgeons from Japan, Korea, Taiwan, and the USA, etc. ( n = 614) participated in a questionnaire regarding their BDI experience and near‐misses; and perceptions on landmarks, intraoperative findings, and surgical techniques. Respondents voted for a Delphi process and graded each item on a five‐point scale. The consensus was built when ≥80% of overall responses were 4 or 5. Response rates for the first‐ and second‐round Delphi were 60.6% and 74.9%, respectively. Misidentification of local anatomy accounted for 76.2% of BDI . Final consensus was reached on: (1) Effective retraction of the gallbladder, (2) Always obtaining critical view of safety, and (3) Avoiding excessive use of electrocautery/clipping as vital procedures; and (4) Calot's triangle area and (5) Critical view of safety as important landmarks. For (6) Impacted gallstone and (7) Severe fibrosis/scarring in Calot's triangle, bail‐out procedures may be indicated. A consensus was reached among expert surgeons on relevant landmarks and intraoperative findings and appropriate surgical techniques to avoid BDI .
Relationships of Clinical and Computed Tomography-Imaged Adiposity with Cognition in Middle-Aged and Older African Americans
Parker, Kirby G., Lirette, Seth T. , Deardorff, David S, Bielak, Lawrence F. , Peyser, Patricia A. , Carr, J. Jeffrey , Terry, James G. , Fornage, Myriam , Benjamin, Emelia J. , Griswold, Michael , Windham, B. Gwen , Turner, Stephen T. , Benjamin, Emelia J , Mosley, Thomas H. , Terry, James G , Lirette, Seth

Mayo Clinic

The Journals of Gerontology: Series A | August 31, 2017 | Volume: 73 | Issue: 4 | Pages: 492-498

10.1093/gerona/glx163 | PMID 28958070 Get It

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Boorjian, Stephen A. , Canter, Daniel , Ogan, Kenneth , Downs, Tracy M. , Gomella, Leonard G. , Svatek, Robert S. , Bivalacqua, Trinity J. , Grubb, Robert L. , Krupski, Tracey L. , Inman, Brant A. , Milowsky, Matthew I. , Boyd, Alan , Treasure, F. Peter, Gregory, Gillian , Sawutz, David G., Parker, Nigel, Dinney, Colin P. , Canter, Daniel J, Karsh, Lawrence I, Woods, Michael E. , Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N, Inman, Brant A , Shore, Neal D. , Karsh, Lawrence Ivan , Kamat, Ashish M. , Lotan, Yair , Lerner, Seth P. , Ylä-Herttuala, Seppo

Mayo Clinic

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 30 | Pages: 3410-3416

10.1200/jco.2017.72.3064 | PMID 28834453 Get It

Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590)
Bhatia, Aarti , Lee, Ju‐Whei, Pinto, Harlan A. , Jacobs, Charlotte, Rubin, Philip, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth A., Báez-Díaz, Luis , Celano, Paul , Li, Yi , Burtness, Barbara , Adams, George L. , Pandya, Kishan J., Bhatia, Aarti K , Limburg, Paul J. , Burtness, Barbara , Lee, Ju‐Whei , Li, Shuli

Mayo Clinic

Cancer | August 7, 2017 | Volume: 123 | Issue: 23 | Pages: 4653-4662

10.1002/cncr.30920 | PMID 28786105 Get It

BACKGROUND13‐Cis retinoic acid (13‐CRA) is a synthetic vitamin A derivative. High‐dose 13‐CRA in patients with squamous cell cancers of the head and neck (SCCHNs) reduces the incidence of second primary tumors (SPTs). The authors report long‐term results from a phase 3 randomized trial that compared treatment with low‐dose 13‐CRA versus placebo for patients who had early stage SCCHN, with a focus on the development of SPTs and overall survival (OS).METHODSIn total, 176 patients who received treatment for stage I/II SCCHN were randomized to receive either low‐dose 13‐CRA (weight‐based dose of 7.5 mg or 10 mg) or placebo for 2 years. A competing‐risk approach and the log‐rank test were used to compare the time to SPT and OS, respectively, between groups.RESULTS13‐CRA neither significantly reduced the cumulative incidence of SPT (P = .61) nor improved the time to SPT (hazard ratio [HR] for 13‐CRA/placebo; 0.86; P = .61). Despite limited power, there was a trend toward improved OS for the 13‐CRA arm (HR, 0.75; P = .14), particularly among patients whose index tumor was surgically excised (N = 26; HR, 0.50; P = .057) and among women (N = 39; HR, 0.44; P = .065) and never/former smokers (N = 129; HR, 0.61; P = .055), with a median follow‐up of 16 years. The main 13‐CRA related toxicities were dry skin and cheilitis.CONCLUSIONSTreatment with low‐dose 13‐CRA for 2 years did not decrease the incidence of SPT; subset analysis indicates a potential survival advantage among patients who are women and never/former smokers. More targeted interventions based on clinical risk factors and molecular characterization of tumors may yield greater success in future prevention trials. Cancer 2017;123:4653‐4662. © 2017 American Cancer Society.